Last reviewed · How we verify

Multiple Myeloma — Treatment Landscape & Competitive Intelligence

Multiple Myeloma (Oncology / Haematology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Oncology / Haematology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Multiple Myeloma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pf-07293893 pf-07293893 Pfizer JAK inhibitor Janus kinase (JAK) pathway Not available
Pf-07220060 pf-07220060 Pfizer Small molecule inhibitor Specific protein involved in disease pathways Not available
Pf-07248144 pf-07248144 Pfizer Small molecule inhibitor Specific protein involved in disease pathways Not available
Aphexda MOTIXAFORTIDE Ayrmid Pharma 2026-01-01
Blenrep BELANTAMAB MAFODOTIN GSK BCMA 2020-01-01
Darzalex daratumumab Johnson & Johnson Monoclonal antibody CD38 2015-01-01
Ninlaro IXAZOMIB Takeda Proteasome Inhibitor Proteasome subunit beta type-5 2015-01-01
Huluc63 elotuzumab Bristol-Myers Squibb SLAMF7-directed Immunostimulatory Antibody [EPC] SLAM family member 7 2015-01-01
Farydak PANOBINOSTAT Secura Histone Deacetylase Inhibitor Histone deacetylase 4 2015-01-01
Pomalyst pomalidomide Bristol-Myers Squibb Thalidomide Analog [EPC] Protein cereblon 2013-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 14 drugs in Multiple Myeloma
  2. Bristol-Myers Squibb · 4 drugs in Multiple Myeloma
  3. Baxter · 3 drugs in Multiple Myeloma
  4. Sanofi · 2 drugs in Multiple Myeloma
  5. Pfizer Inc. · 2 drugs in Multiple Myeloma
  6. Black Sea Hematology Association · 1 drug in Multiple Myeloma
  7. French Innovative Leukemia Organisation · 1 drug in Multiple Myeloma
  8. Apotex · 1 drug in Multiple Myeloma
  9. Duke University · 1 drug in Multiple Myeloma
  10. Chipscreen Biosciences, Ltd. · 1 drug in Multiple Myeloma
  11. Ayrmid Pharma · 1 drug in Multiple Myeloma
  12. Bristol · 1 drug in Multiple Myeloma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Multiple Myeloma:

Cite this brief

Drug Landscape (2026). Multiple Myeloma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/multiple-myeloma. Accessed 2026-05-14.

Related